JP Morgan Chase’s Hemab Therapeutics COAG Stock Holding History
Bought
Maintained
Sold
Other funds holding COAG
SL
JP Morgan Chase's COAG Position: Q3 2026 in Review
JP Morgan Chase reduced its Hemab Therapeutics (COAG) stake by 19% in Q3 2026, selling an estimated $9.6M and leaving 932,857 shares worth $30.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.
JP Morgan Chase first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. The position peaked at $42.3M in Q2 2026. 66 funds tracked by Wall St. Rank hold COAG as of Q3 2026.
- JP Morgan Chase held 932,857 shares of Hemab Therapeutics worth $30.4M as of Q3 2026.
- JP Morgan Chase sold 219,563 Hemab Therapeutics shares in Q3 2026, an estimated $9.6M.
- Hemab Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #1856 holding.
- JP Morgan Chase first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
- JP Morgan Chase's Hemab Therapeutics position peaked at $42.3M in Q2 2026.
- 66 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.